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1.  Introduction
Organizations are a reflection of their lead-
ers, as Hambrick and Mason (1984) proposed 
in the upper echelon theory. Many researches 
has done to study the relationships among chief 
executive officer (CEO) characteristics, top 
management team diversity and the firm per-
formance, following the theory, and there is no 
right answer on these arguments while it gave 
us numerous indicators to analyze the organiza-
tions. 
The ability to manage the firm is also depend-
ing on its dominant logic, which consists of “a 
mindset, experience, the administrative tools 
to accomplish goals and making the decisions 
in the business” (Prahalad and Bettis, 1986). To 
survive the changes in the industry, evolution of 
the dominant logic in the firm is occasionally 
required to reorient the strategy. In that sense, 
CEOs must be able to scan industry future sce-
narios so that timely decisions can be made, 
following the firm’s dominant logic, which is 
developed over their experience.
Then what kind of the CEOs can be the best? 
Hambrick and Mason (1984) presented the 
indicators to find the firm performance, such as 
CEO age, functional tracks, other career experi-
ences, education, socioeconomic roots, financial 
position and group characteristics. The range 
of indicators were extended by many others. 
Besides these indicators above, CEO origins 
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(insider/outsider), tenure, age, were added to 
see the relationship of the firm’s R&D spending 
(Datta and Guthrie, 1994; Baker and Mueller, 
2002).
Managerial characteristics of CEOs were 
examined as well. CEOs with a master of busi-
ness administration (MBA) degree were ana-
lyzed, and the result showed they tended to 
choose in higher level of capital expenditures, 
hold more debt and pay less dividends. (Ber-
trand and Schoar, 2003) CEOs with MBA degree 
also had a positive association with corporate 
environmental performance (Slater and Dixon-
Fowler, 2010).
Although CEO characteristics and the firm 
performance have been studied in many ways, 
the comparative study on CEOs including Japa-
nese firms has not done many. The diversity in 
the organization did not have the clear defini-
tion until recently and still has been discussed 
(Arimura, 2008). The studies of the diversity in 
the Japanese top management is still hard to 
find.
When we look at the pharmaceutical industry 
and market analysis, the sales growth of Japa-
nese pharmaceutical firms is not as big as the 
ones of the other countries in the past 18 years.1 
There might be some relationship among CEO 
characteristics and the market situation Japa-
nese pharmaceutical firms are facing.
Focusing on the pharmaceutical industry, this 
paper examines whether the relationships exist 
among the CEO characteristics (MBA hold-
ers and CEO tenure), CAGR, and the industry 
characteristics (firm age and firm size) sorted by 
six divided world regions to see the difference 
among them and Japan.
2.   Pharmaceutical Industry, 2001 
to 2018 
Pharmaceutical firms need a long term busi-
ness strategy of research & development and 
investment to develop an innovative drug. The 
industry is stable2, however the overall econom-
ic, regulatory, social and political conditions can 
affect their performance. The market and peo-
ple’s lifestyles influence their performance as 
well as the expiration of their drug patents. An 
innovative drug that holds a long term patents 
will mostly turn into a blockbuster drug. It earns 
the annual sales of at least $1 billion for the firm 
(Hannigan, Mudambi and Sfekas, 2013).
While there are three kinds of ethical phar-
maceutical firms in general, this study is focus-
ing on the firms that needs the long term 
business strategy including manufacturing and 
distributing their products. This kind of firms is 
called the mainline pharmaceutical firms. They 
develop new innovative drugs, and spend a huge 
amount on R&D, and have variety of drugs in 
their pipeline. Some of them have various divi-
sions that handle OTC and animal drugs.3
Besides the mainline pharmaceutical firms, 
there are the research and development phar-
maceutical firms, and the generic pharmaceuti-
cal firms. These three types of pharmaceutical 
firms have a different range of R&D investments 
and the resources. The R&D pharmaceutical 
firms focus on research to develop a new drug 
while being invested in by some other firms as 
well. The generic pharmaceutical firms do not 
need to spend a long time nor the large cost to 
develop their drugs. 
Most of the mainline pharmaceutical firms 
prepare various strategies before the patent 
expiry of their blockbuster drugs. The popular 
strategies such as mergers and acquisitions, 
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co-marketing, sales partnerships and licensing 
are taken while they invest enormous amounts 
on R&D to find the next blockbuster drug. 
The world’s top class of pharmaceutical firms 
never stop challenging these actions until they 
find a new drug that can extend its long patent 
retention. Keeping a patented blockbuster drug 
continuously is a matter of survival for the phar-
maceutical industry. 
It looks as if Japanese pharmaceutical firms 
also have been struggling to grow their perfor-
mance more than other countries. When we 
look at the sales ranking of the world’s top 20 
pharmaceutical firms in 2001, there were eight 
Japanese firms listed in the ranking. Takeda 
Pharmaceutical was ranked in top 10. Following 
Takeda, Astellas Pharma, Shionogi, Kyowa Hak-
ko Kirin, Eisai, Chugai Pharmaceutical, Mitsubi-
shi Tanabe Pharma, and Sumitomo Dainippon 
Pharma were ranked in top 20. 
However, the number of Japanese firms on 
the list has decreased every year. As a result, 
there are only three firms listed in 2018 
(Figure 1). Takeda Pharmaceutical was ranked 
in top 14, Astellas Pharma was in top 18, and 
Otsuka Holdings was in top 19. European firms 
increased their numbers, and USA firms stayed 
as it is. There are two Chinese firms from 2016.4
Why did the number of the Japanese firms in 
top 20 decrease in 18 years? What is the differ-
ence between Japanese firms and others? There 
can be tons of reasons, however there will be 
no right answer. Fewer firms in the top 20 rank-
ing do not mean that their sales dropped in 
the 18 years. Actually, the sales of all the firms 
increased rather than dropped or stayed the 
same. Then why did the pharmaceutical firms in 
other countries grow more than Japanese phar-
maceutical firms?
While business strategies can be different for 
each firm, the assumption is that there can be 
cultural difference in the business strategies by 
each region. The management team can differ 
as well.
A CEO can influence a critical organiza-
tion decision. These outcomes reflect the top 
managers and their decisions. (Chaganti and 
Sambharya, 1987; Hambrick and Mason, 1984) 
CEO selection decisions have been studied in 
various areas of organization theory and stra-
tegic management (Datta and Guthrie, 1994). 
However, there is not much research that 
focuses on CEOs in the pharmaceutical industry 
with a stable business environment, compared 
by countries and regions. This paper attempts 
to find out the regional CEO characteristics by 
looking over the industry for 18 years.








































3.   The Patent Expiry Rush of Phar-
maceutical Industry in 2010
A possible reason why these Japanese pharma-
ceutical firms did not grow as good as the one 
in the other regions period from 2001 to 2018 is 
that the Japanese firms were not able to manage 
the “2010 problem.” 
In Japan, the pharmaceutical industry rapidly 
developed from 1975 to 1995. (Thomas, 2005) 
The economic bubble also pushed the expan-
sion of other industries in Japan as well as the 
pharmaceutical industry.  Table 1 shows the first 
year of approval of a well-known blockbuster 
drug as well as its patent expiry. The countries 
listed in the table are the USA, Europe and 
Japan. After the patent expires, the price of the 
drug become almost 70% of the original price, 
then it drops every year until it becomes about 
50%. Generic drugs also will be released and 
take more or the market share. Therefore, the 
sales of the pharmaceutical firms always depend 
on the profit of their blockbuster drugs before 
the patent expiry. 
Most of the drugs in the table were developed 
and launched in 1990’s, which is the time of 
Japanese bubble economy. When we look at the 
years of patent expiry, it shows the expiries hap-
pened right before and after 2010. That is called 
“2010 problem of the Pharmaceutical Industry” 
in Japan.5
This paper examines CEOs in 18 years from 
2001 to 2018. It means that we can review the 
CEOs before and after the patent expiry rush. 
The firms would have difference performances 
before and after, while it may grow well in the 
expiry rush, and some may not. 
4.  CEO Characteristics: Review
4.1  Upper Echelon Theory
In the upper echelon theory (Hambrick and 
Mason, 1984), there are seven characteristics 
Table 1  Year of Patent Expiry of the Blockbuster Drugs around the year of 2010
 
First Yr of
Patent Expiry Product Name Active Ingredient Company Country
First Yr of
Approval
2007 Norvasc Amlodipine Pfizer USA 1990
2010 Paxil  Paroxetine GSK England 1992
2008 Prograf  Tacrolimus Astellas Japan 1993
2009 Takepron Lansoprazole Takeda Japan 1995
2011 Lipitor Atorvastatin Astellas Japan 1996
2012 Diovan Valsartan Novartis Switzerland 1996
2012 Plavix Clopidogrel Sanofi France 1997
2013 Rituxan Rituximab Biogen/Roche USA/Switzerland 1997









2012 Viagra Sildenafil Pfizer USA 1998
2010 Aricept Donepezil Eisai Japan 1999
2011 Actos Pioglitazone Takeda Japan 1999
2014 Nexium Esomeprazole AstraZeneca England 2000
2008 Radicut Edaravone Tanabe Mitsubishi Japan 2001
2016 Humira Adalimumab AbbVie USA 2002
2019 Avastin
* source: own research
Bevacizumab Roche Switzerland 2004
CEO characteristics comparison by region in the pharmaceutical industry: 2001 ‒ 2018
－63－
presented such as age, functional tracks, other 
career experiences, education, socioeconomic 
roots, financial position and group character-
istics. Expanding the theory, there is various 
studies on the CEO characteristics. CEO age is 
related with the frequency of acquisition activ-
ity. Younger CEOs in 20’s is 30% less likely to 
pursue acquisition (Yim, 2013). Herrmann and 
Datta (2002) examined CEO position tenure, 
educational level, functional background and 
international experience as CEO characteristics 
to determine decisions when they expanded the 
business outside of their origin country. 
The characteristics mentioned above can 
influence the strategic choices, according to the 
upper echelon theory. Eleven choices are con-
sidered, including product innovation, acquisi-
tion, plant and equipment newness, forward 
integration, financial leverage, and administra-
tive complexity. These influence profitability, 
variations in profitability, growth and survival. 
Datta and Rajagopalan (1996) reported that 
industry structure influences the characteristics 
of the CEO successor. The research indicates 
that the higher industry growth rate, the shorter 
organizational tenure and age of the CEO 
successor. Firm size, growth rate and industry 
concentration would affect CEO age, position 
tenure, and background, especially in the larger 
product differentiation.
4.2  CEO Position Tenure
Eitzen and Yetman (1972) analyzed the 
basketball team to find the best length of the 
leader’s tenure. It showed that the team per-
formance dropped rapidly after 13 years while 
the longer period of leadership could have the 
great team success. To analyze the reason of 
why the team performance dropped after 13 
years, Hambrick and Fukutomi (1991) analyzed 
it in the top management team by finding five 
phases of CEO tenure. It showed extremely 
short and extremely long CEO tenures would be 
harmful. Miller (1991) found that the negative 
impact likely happened when a CEO left after 
the long tenure. The next CEO usually had dif-
ficulty accomplishing their new goals. 
On the other hand, the short CEO tenure 
also gives a negative impact on their perfor-
mance (Shen and Canella, 2002). When the 
firms replace their CEOs in a short term, the 
new CEO is not able to build trust in the orga-
nization. Pharmaceutical firms need a long-
term strategy while increasing R&D spending. 
Hambrick and Fukutomi (1991) also pointed 
out that a CEO reduces the range of industry 
interest, or narrows the information preference. 
The above arguments suggest that the CEO ten-
ure in pharmaceutical firms should not be short 
while the longer tenure may not have needed 
changes and product development. 
4.3  CEO with MBA degree
It is often discussed that CEOs have an impor-
tant role in firm’s performance and innovations 
in the industry (Agle et al., 2006; Darmadi, 
2011). CEOs with an administrative education 
degree like an MBA are studied empirically 
to check their performance (Gottesman and 
Morey, 2006). There are also critics for MBA 
(Mintzberg and Lampel, 2001). Basically, no 
matter the arguments whether an MBA is posi-
tive or not, the CEO with an MBA has never 
diminished an existing firm. They still exist - 
meaning the firms find some kind of benefits by 
having such a CEO.
According to “The Best-Performing CEOs in 
the World 2018” by Harvard Business Review, 
there were 32 MBAs out of 100 CEOs in the list. 
21 are from USA, 10 from Europe, and 1 from 
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Hong Kong. There were 4 Japanese CEOs in the 
list, but none of them had MBA. The list indi-
cates that MBA is one of the important factors 
to evaluate the success of a CEO. 
As mentioned, in Japan, MBA is underesti-
mated in the firm. The list predicted that there 
would be not many MBAs in Japanese pharma-
ceutical firms. A CEO with an administrative 
degree is often involved however, in the phar-
maceutical industry, the business is also a matter 
of innovation, R&D, patents, and life science. In 
the business strategies, the possibility of a CEO 
with various kinds of degrees may be selected. 
The CEOs in the pharmaceutical industry may 
show some characteristics similar to other indus-
tries. 
5.  Method
5.1  Sample and Data Sources
This study was based on 318 CEOs in 158 
mainline pharmaceutical  f irms from 21 
countries out of 328 firms, that were listed in 
SPEEDA.6 These firms were publicly listed, and 
had at least 20% of sales of prescription drugs 
(not in generic drugs), according to SPEEDA 
industry categories.  It means that prescription 
drug sales and R&D were the main business 
focus of the firm. Firms in socialist countries 
were excluded such as China and Vietnam. This 
study focused on 18 years from 2001 to 2018, 
which spans the 2010 problem of the pharma-
ceutical industry. 
CEOs of each firm in 18 years were studied at 
S&P Capital IQ Platform7 (hereinafter referred 
to Capital IQ) and the firm’s own website. The 
names of 318 CEOs were found, and data was 
collected about their CEO starting with age, 
educational background and tenure. 
The data of the firm’s age, size (as the num-
ber of employees), and CAGR of 18 years were 
gathered as well from Capital IQ and firm web-
site. The 158 firms were divided into 6 regions; 
Europe, USA with Canada and Australia, Japan, 
Korea, India and the others including Malaysia, 
Indonesia and Egypt, to see any characteristics 
by regions. 
Sorting out the data by each region, the firm 
and CEO data were analyzed. 
5.2  Measures and Variables
While Hambrick and Mason (1984) men-
tioned CEO age, functional tracks, other career 
experiences, education, socioeconomic roots, 
financial position and group characteristics, 
this paper selected firm age, firm size to see the 
characteristic of the pharmaceutical industry, 
CAGR for sales to see its performance, and CEO 
tenure and CEO MBA education as the CEO 
characteristics. 
In order to find out possible explanations for 
any discovered relationship, measures for vari-
ables were described as follows;
Firm Age
To find out the firm age, 2018, was subtracted 
from the founded year. The firms in the list were 
from various regions mixing of developing and 
developed countries. Depending on the regions, 
the history of their pharmaceutical industry 
could be different. Evans (1987) reported that 
the firm age determines of firm dynamics. 
Firm Size (Employees)
The number of employees was often used to 
see the firm size in the organizational learning 
study. (Gordon et al., 2000) It is also proper 
to see the amount of property, sales, and new 
employments such as from M&A. (Yasuda, 
2005) The number of employees was collected 
as data together with the firm age in 2018 Some 
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of the firms might have gotten bigger or smaller 
by M&A or liquidation in 18 years, therefore the 
number in 2018 was taken to represent the lat-
est firm condition.
CAGR (Compound Annual Growth Rate) for 
Sales
The CAGR from 2001 to 2018 was examined. 
The performance of the CEO in 2000 would 
have been represented at the balance of 2001. 
Therefore, this study made the balance of 2001 
as the starting period of CAGR. CAGR was cal-
culated as below. 
When the firm did not have the balance in 
2001, the balance of the year they started was 
used. The CAGR of each firm was calculated, 
then combined and averaged by regions.  
CEO Tenure
The CEO tenure was calculated by subtract-
ing the year beginning as CEO from the year of 
resigning as CEO. 
CEO MBA Education
In this study, the number of CEOs with an 
MBA was counted in their educational back-
ground.  
6.  Results and Findings
Table 2 provides minimum, maximum, means 
and standard deviations of each variable. It 
shows variety of the firm age and size. The old-
est firm was Fresenius SE & Co. KGaA, Germany, 
founded in 1462. The youngest firm was Abbvie, 
Inc, USA, founded in 2012. 
The longest CEO tenure was 49 years. Four 
Japanese CEOs had their position for over 30 
years. Four of South Korean CEOs had their 
position for over 40 years. Three out of 4 were 
founders of the firm. Three Indian CEOs had 
their position for over 30 years. They were all 
founders of the firm. 
Table 3 shows sorted data by each region. 
There were 64 firms in South Korea, while USA 
area had only 10 firms. South Korea firms were 
younger over all, as well as smaller. (Employ-
ees ≤468) It suggests that the firms in the USA 
merged and grew while the firms in South Korea 
remained in the stage of a developing market. 
While the firms in South Korea had a higher 
CAGR, Indian firms had really lower rate of 
-12%. It might have indicated the Indian firms 
were still in the stage of R&D investing rather 
than making bigger sales since most of the firms 
were founded less than 50 years. In 2018, there 
was no well-known new drug developed in South 
Korea or India. Most of the top sales drugs in 
the world developed by firms in Europe, USA or 
Japan.8
Table 3 also shows the comparison of CAGR 
by each region. The CAGR of Japanese firms 
was one of the lowest after Indian firms. It could 
explain the reason why Indian firms had such 
low CAGR because they were still medium sized, 
young and not having new drugs in the global 
Table 2  Descriptive Statics (N=158)
N Minimum Maximum Mean Std. Deviation
Firm Age 158 6 556 79.9 72.20
Employees 137 7 276,750 13,028.8 34,893.70
CEO Tenue 103 1 49.0 12.4 10.24
Valid N (listwise) 89
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top sales. However, it is hard to assume why 
Japanese firms had one of the lowest CAGR, 
especially compared with the big two regions, 
Europe and USA.
Japanese firms were well-established, around 
120-year-old on average, which was older than 
firms in USA. The firm size, as the number of 
employees, was actually eight to ten times small-
er than the ones in Europe and USA. 
CEO tenure of Japanese firms was not the 
longest but there were two groups clearly; one 
was Europe and USA, the other was the rest of 
world. An average of 7 years of CEO tenure and 
average 13-15 years of tenure, which was twice as 
long than in Europe and USA. 
The CEO in the regions other than the 
Europe and USA had longer tenure, and 
CAGRs in these countries were not as high as 
the Europe and USA. The countries in the “oth-
ers,” included Egypt, Saudi Arabia, Malaysia and 
Indonesia, had higher CAGR compared with 
Japan, South Korea and India. Consequently, 
Japanese firms had the lowest CAGR and the 
longest CEO tenure in the three big pharma-
ceutical markets, Europe, USA and Japan. 
Table 4 shows the number of CEOs with an 
MBA degree by each region. In Japan, there 
was only 7% of CEOs who had an MBA degree, 
which was extremely low compared with other 
regions.  The highest rate of CEO with an MBA 
degree was 44% in the USA. The next highest 
was 32% in the Europe, then the other regions 
had around 20%. 
Japanese firms had the lowest rate of MBA 
holders. However, Indian firms had the lowest 
CAGR with 25% holders of an MBA. As men-
tioned, the industry environment of Japan and 
India could be different since India was still 
developing in the pharmaceutical industry. 
Table 5 shows the correlation of these vari-
Table 3  Descriptive Statics by Region
Europe 20 159.4 52,181 7.55 8.3%
USA, Canada,
Australia 11 100.4 43,400 7.16 10.4%
Japan 30 119.6 5,886 14.30 3.3%
South Korea 64 49.3 468 15.35 6.0%
India 23 48.7 2,309 13.50 -12.1%


























Japan 74 5 7%
South Korea 106 26 25%
India 28 7 25%
Others 20 4 20%
Total 318 75
*Source : Data collected from Capital IQ and the websites of each firm
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ables to examine any relationship with CAGR, 
CEOs with MBA degree and CEO tenure. Unfor-
tunately, there was no correlation among these 
variables. As the firm became older, the size got 
bigger, then there would be more chances to 
have CEOs with MBA. Therefore, there was no 
surprise that the amount of MBA holders had 
a correlation with the firm’s age and size. As 
well as CEO tenure, the older firms had a more 
chance for CEOs to have longer tenure. 
7.  Discussion
There are five findings that we can compare. 
One is the number of the pharmaceutical firms 
in each region, the other is CEO tenure by 
region, the next is the numbers of MBAs in each 
region, then the CAGR by region, and the last is 
that no correlation was found among these vari-
ables. 
Firstly, there were 64 South Korean firms out 
of 158 pharmaceutical firms, 23 in India, and 
30 in Japan, while 20 in Europe, and only 11 
in USA with Canada and Australia and all were 
public-listed.9 This allocation of the number of 
the firms might indicate the pharmaceutical 
market structure. Obviously, the firms in USA 
were acquired and merged, and the size grew. 
According to Japan Pharmaceutical Manufactur-
ers Association (JPMA), there were 19 pharma-
ceutical firms in the USA in 1990’s.10 In 30 years 
towards 2018, it turned into 9 firms. It means 
that it is likely Japanese, South Korean and Indi-
an firms will be acquired or will merge gradually 
in the future, similar to the USA pharmaceutical 
industry. 
Secondly, there was a clear difference in 
CEO tenure between Europe and USA on one 
side, and the others. The first two regions had 
around 7 years’ average, while the other regions 
had around 14 years. The average of CEO ten-
ure in all region is 12.09 years. It supports what 
Hambrick and Fukutomi (1991) discussed. The 
team performance drops rapidly after 13 years, 
so firms have no choice but to replace the CEO 
to keep the performance (Eitzen and Yetman, 
1972).
Table 5  Correlations
AGE
FIRM SIZE
(employees) CAGR CEO Tenue MBA Holders
Pearson Correlation 1 .709 ** 0.053 -0.188 .208 **
Sig. (2-tailed) 0.000 0.509 0.057 0.009
N 158 137 157 103 158
Pearson Correlation .709** 1 -0.002 -.206* .288**
Sig. (2-tailed) 0.000 0.979 0.048 0.001
N 137 137 137 93 137
Pearson Correlation 0.053 -0.002 1 -0.021 0.028
Sig. (2-tailed) 0.509 0.979 0.830 0.727
N 157 137 157 103 157
Pearson Correlation -0.188 -.206* -0.021 1 -0.174
Sig. (2-tailed) 0.057 0.048 0.830 0.078
N 103 93 103 103 103
Pearson Correlation .208** .288** 0.028 -0.174 1
Sig. (2-tailed) 0.009 0.001 0.727 0.078
N 158 137 157 103 158
CEO Tenue
MBA Holders
**. Correlation is significant at the 0.01 level (2-tailed).







Thirdly, the number of MBA holders were 
clearly different among these areas. Europe 
and USA had over 30% of MBA holders as their 
CEOs, around 20-25% in South Korea, India 
and the other region, and only 7 % in Japan. 
Firms in Europe and USA might have encour-
aged their shareholders and investors by replac-
ing the CEO occasionally, and increasing their 
CEOs with MBA degrees, as a management 
professional. In contrast, Japan had only 7% as 
CEO with MBAs and the average CEO tenure 
was around 14 years. It might indicate that the 
Japanese firms were still running as family busi-
nesses, and did not consider how to encourage 
their shareholders. An MBA degree does not 
help to be promoted nor their salary in Japan, 
while MBAs in USA are paid better than non-
MBAs. Underestimating the managerial educa-
tion of CEOs in the organization can be one of 
the reasons why the Japanese pharmaceutical 
firms have been losing their presence over the 
past years.
Fourthly, the CAGR by region indicates that 
Japanese pharmaceutical firms lost their stand-
ing in 18 years from 2001 to 2018 when com-
pared with European and USA firms. Japan had 
been decreasing in firms in top 20 sales in the 
world since 2001. Although their CAGR was still 
above 3%, it was not as much as the firms in 
Europe and USA. 
Lastly, no correlation was found relating Japa-
nese firms with negative CAGR and CEOs with 
MBA degrees and longer CEO tenure. It indi-
cates that there may be other reasons for Japan’s 
low CAGR. The research should be continued.
8.   Limitations and Future  
Research
This study focused on the pharmaceutical 
industry, and the data was sorted by firms and 
regions while 318 CEOs examined. While CEO 
characteristics by region were identified, the 
characteristics of each CEO of 18 years were not 
compared individually. If the performance of 
each CEO in their tenure could be studied, the 
educational background data may be more per-
suasive. 
In addition, in upper echelon theory, there 
were other CEO characteristics listed, such as 
functional backgrounds and career roots. Since 
there were another difference beside the num-
ber of MBA, the other characteristics could be 
different indicators of the CEO. 
There can be the difference of CEO criteria 
and the business strategy among Japanese firms 
and the firms in the other regions, as the result 
of the number of CEO with MBA holders. As 
mentioned, some of Japanese firms may be run 
by family so that they focus on keeping the firms 
as it is not on making the firm grow by taking 
the risk of developing blockbusters. 
Regarding the firm size, the number of 
employees in 2018 was compared in this study 
as the result of 18 years. However, some of the 
firms had M&A in the period, and the CEOs 
who made the decision could have been speci-
fied. The comparison of these CEO characteris-
tics will be needed to find out which CEO char-
acteristics move into M&A.
9.  Conclusion
The question of this study, “why Japanese 
pharmaceutical firms have low growth rate in 
18 years,” was not clearly answered by examin-
ing the relationship among CAGR, the number 
of CEO with MBAs and the CEO tenure. How-
ever, there was an obvious difference of CEO 
characteristics in three big regions of the phar-
maceutical market – Europe, USA and Japan. 
The CEOs in Japanese firms rarely had MBA 
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degrees, which could improve a management 
professional. The CEO tenure was twice as long 
as the other two regions, which also might have 
indicated Japanese firms preferred not replac-
ing the CEOs often to present a better image 
to shareholders although performance was not 
always good. 
As a result, these two findings could be the 
reasons of why the Japanese pharmaceutical 
firms did not have higher performance in these 
18 years. 
Notes
1 According to “The Global Use of Medicine in 
2019 and Outlook to 2023” reported by IQVIA 
Institute, Japan’s overall growth will be the slow-
est among the developed markets, and it also was 
from 2014 to 2018. 
2 Desjardins, Jeff, “Visualizing the Future of the 
Pharma Market”, January 30, 2019; https://www.
visualcapitalist.com/future-pharma-market/ [ac-
cessed 2 July 2019]
 According to the data on this page, the popula-
tion growth will never go down as well as aging 
population. It means that the pharmaceutical 
market never shrinks as long as there are patients. 
Most of the drug sales will be increased in years, 
following the aging population. 
3 The innovative drugs produced by the mainline 
pharmaceutical firms are also called “brand name 
drugs.”
4 These two are from Shanghai and Hong Kong. 
Both are the mainline pharmaceutical firms, how-
ever they make the most of the sales from generic 
drugs and their distribution. The reason of be-
ing in the list is not because of their blockbuster 
drugs but because of the economics of scale.(Tou 
and Kanayama, 2015)
5 Business Policies of the Japan Pharmaceutical 
Manufacturers Association for Fiscal 2010(as of 
January 20, 2010), JPMA website, http://www.
jpma.or.jp/english/about_us/policy _activities.
html
6 SPEEDA: Asia’s Leading Platform for Analyses on 
Companies, Industries and M&A Deals, https://
www.ub-speeda.com
7 Capital IQ: A technology and financial services 
company that acts as the research division of 
Standard and Poor’s, https://www.capitaliq.com/ 
8 Global Data, Top 50 Pharmaceutical Products by 
Global Sales (2016),  http://www.pmlive.com/
top_pharma_list/Top_50_pharmaceutical_produ
cts [accessed 2 July 2019]
9 Nine firms in USA, 1 in Canada, and 1 in Austra-
lia.
10 Japan Pharmaceutical Manufacturers Association, 
“M&A in Pharmaceutical Industry (Worldwide),” 
DATA BOOK 2019; A1-6.
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